FindTrial
Sign In

ADC

DRUG5 trials

Sponsors

Fudan University, Peking University First Hospital, MBrace Therapeutics, Peking University Cancer Hospital & Institute

Conditions

Breast CancerColo-rectal CancerLung Cancer (Non-Small Cell)Metastatic Breast Cancer ( HER2 Negative)Pancreas Cancer, Duct Cell AdenocarcinomaProstate Cancer Castration-resistant Prostate CancerUpper Tract Urothelial CarcinomactDNA

Phase 1

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RecruitingNCT07145255
MBrace TherapeuticsBreast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell) +2
Start: 2025-09-03End: 2029-12-30Target: 150Updated: 2026-02-17

Phase 2

ctDNA-guided Treatment Decision-making
RecruitingNCT07394218
Fudan UniversityctDNA, Metastatic Breast Cancer ( HER2 Negative)
Start: 2025-12-24End: 2028-12-31Target: 122Updated: 2026-02-06
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Not yet recruitingNCT07527806
Peking University Cancer Hospital & InstituteBreast Cancer
Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17

Unknown Phase

The Rechallenge of ADCs in MBC Patients
Active, not recruitingNCT05571618
Fudan UniversityBreast Cancer
Start: 2022-09-01End: 2025-03-01Target: 100Updated: 2024-10-21
HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study
Not yet recruitingNCT06798246
Peking University First HospitalUpper Tract Urothelial Carcinoma
Start: 2025-02-01End: 2030-01-01Target: 200Updated: 2025-01-29